Cadence Biomedical

Cadence Biomedical, headquartered in Seattle, WA, is an early-stage medical device company that is committed to helping the 2.3 million Americans who suffer severe mobility impairments to gain a more mobile and independent life.

Cadence Biomedical's primary commercial product, Kickstart, is a neurorehabilitation device designed to accelerate recovery to walking in stroke, multiple sclerosis, spinal cord injury patients, and individuals with other progressive neurological conditions. Kickstart is available for use in physical therapy during the initial recovery process and as a prescribed device for post-discharge use in the community and home settings.

The company is currently developing a new class of device, a kinetic orthosis, based on a novel exotendon technology invented at the Cleveland Clinic by world-renowned researcher Dr. A.J. van den Bogert. Cadence closed its first round of funding in August 2010 (as Empowering Engineering Technologies, Corp.) and signed a perpetual, worldwide exclusive license agreement with the Cleveland Clinic to develop and market the technology. Market release of the kinetic orthosis is expected in early 2012.

Cadence Biomedical headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical Device sector. The company focuses on Biotechnology and has secured $244.0M in funding across 80 round(s). With a team of 11-50 employees, Cadence Biomedical is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Cadence Biomedical, raised $750.0K. Discover more about their projects, partnerships, and impact on our platform.